Market Place
Sourcing Support
Santhera and ReveraGen Announce FDA Acceptance of NDA for Vamorolone
09 Jan 2023 //
GLOBENEWSWIRE
Penny stock forges ahead with an NDA for Duchenne, seeking priority review
28 Oct 2022 //
ENDPTS
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone
27 Oct 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce Presentations on Efficacy and Bone Health in DMD
10 Oct 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce 1st Participant Dosed in FDA-funded PII study
22 Aug 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 PPMDC
09 Jun 2022 //
GLOBENEWSWIRE
Santhera, ReveraGen Start Rolling NDA Submission to FDA for Vamorolone in DMD
29 Mar 2022 //
GLOBENEWSWIRE
Santhera, ReveraGen to Present Efficacy & Safety Data with Vamorolone at MDA
14 Mar 2022 //
GLOBENEWSWIRE
Santhera, ReveraGen announce positive topline results with vamorolone
24 Nov 2021 //
PHARMABIZ
Santhera & ReveraGen Announce +veTopline Results with Vamorolone
23 Nov 2021 //
GLOBENEWSWIRE
Santhera und ReveraGen geben erfolgreiches FDA-Pre-NDA-Meeting für Vamorolone
17 Nov 2021 //
GLOBENEWSWIRE
Santhera &ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone
17 Nov 2021 //
GLOBENEWSWIRE
ReveraGen and Santhera Announce FDA Orphan Grant Funding
27 Sep 2021 //
GLOBENEWSWIRE
Santhera and ReveraGen to Present Phase 2a/2b Efficacy
23 Sep 2021 //
GLOBENEWSWIRE
Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study
24 Jun 2021 //
GLOBENEWSWIRE
ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant
17 Nov 2020 //
MORNINGSTAR
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone
02 Sep 2020 //
GLOBENEWSWIRE
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
02 Sep 2020 //
FIERCEBIOTECH
Santhera Announces Completion of ReveraGen’s Long-Term Study with Vamorolone
01 Jun 2020 //
GLOBENEWSWIRE
ReveraGen reports positive data for vamorolone in DMD
28 Aug 2019 //
CLINICALTRIALSARENA
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.